Recombinant hemagglutinin influenza vaccine
Recombinant hemagglutinin influenza vaccine has been studied in 1 paper since 2016: 1 trial in people. The newest paper, Jan 19, 2016: “Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans”.
1 paper studies it1 findingUpdated
See all 1 papers on recombinant hemagglutinin influenza vaccine
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Adults showed the highest induction of stalk-specific antibodies, but the elderly had the highest absolute antibody titers against the stalk”
- 1 lab in 1 country
- Funders: National Institute of Allergy and Infectious Diseases and 2 more
- 1 of 1 finding with company ties
- Human trial1
Studies in people
1 study gave recombinant hemagglutinin influenza vaccine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Treated cohort | children (6 to 59 months), adults (18 to 49 years), elderly (≥65 years)Midlife adults; Older adults; Across the life course | mBio, Jan 19, 2016 |
What did studies of recombinant hemagglutinin influenza vaccine find?
1Studies of recombinant hemagglutinin influenza vaccine measured one outcome, hemagglutinin stalk-reactive antibodies.
Hemagglutinin stalk-reactive antibodies
upin humans1
1 study
Hemagglutinin stalk-reactive antibodies
upin humans1
Recombinant hemagglutinin influenza vaccine increases hemagglutinin stalk-reactive antibodies in humans.
“Adults showed the highest induction of stalk-specific antibodies, but the elderly had the highest absolute antibody titers against the stalk”
Human trialserum
mBio